Merck KGaA, a leading science and technology company announced a partnership with Oxford University’s Jenner Institute to develop more robust and scalable vaccine manufacturing processes.
This partnership, as well as plans to develop a vaccine manufacturing facility in Ghana, further the company’s commitment to improving global health by making vaccines more affordable and available.
Through the collaboration with the Jenner Institute, the partners will improve the manufacturing process for adenovirus vaccines — vaccines based on adenovirus, a type of DNA virus, as a carrier — using Merck products, systems and technologies on a real-world feed stream. By applying Merck technology, the collaborators aim to develop a cost-effective and transferable manufacturing process that can be used to accelerate vaccine development and manufacturing worldwide.
The collaboration should result in a closed process that can be practiced in a cleanroom to minimize contamination, in line with the high biological safety requirements for viral vectors.